Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 9, 2010, Pages 3066-3077

  Karki, Radha ^a   Thapa, Pritam ^a   Kang, Mi Jeong ^a   Jeong, Tae Cheon ^a   Nam, Jung Min ^b   Kim, Hye Lin ^b   Na, Younghwa ^c   Cho, Won Jea ^d   Kwon, Youngjoo ^b   Lee, Eung Seok ^a  

^a Yeungnam University   (South Korea)

^b Ewha Womans University   (South Korea)

^c Catholic University of Daegu   (South Korea)

^d Chonnam National University   (South Korea)

Author keywords

Anticancer agents; Cytotoxicity; Hydroxylated 2,4 diphenyl 6 aryl pyridines; Topoisomerase I and II inhibitor

Indexed keywords

2 [2 (FURAN 2 YL) 6 PHENYLPYRIDIN 4 YL]PHENOL; 2,2' (4 PHENYLPYRIDINE 2,6 DIYL)DIPHENOL; 2,4 DIPHENYL 6 ARYL PYRIDINE DERIVATIVE; 3 (2,6 DIPHENYLPYRIDIN 4 YL)PHENOL; 3 (4 PHENYL 2,4' BIPYRIDIN 6 YL)PHENOL; 3 (4,6 DIPHENYLPYRIDIN 2,6 YL)PHENOL; 3 (6 PHENYL 2,2' BIPYRIDIN 4 YL)PHENOL; 3 (6 PHENYL 2,3' BIPYRIDIN 4 YL)PHENOL; 3 (6 PHENYL 2,4' BIPYRIDIN 4 YL)PHENOL; 3 [2 (FURAN 2 YL) 6 PHENYLPYRIDIN 4 YL]PHENOL; 3 [2 PHENYL 6 (THIOPHEN 2 YL)PYRIDIN 4 YL]PHENOL; 3 [2 PHENYL 6 (THIOPHEN 3 YL)PYRIDIN 4 YL]PHENOL; 3 [4 PHENYL 6 (THIOPHEN 2 YL)PYRIDIN 2 YL]PHENOL; 3 [4 PHENYL 6 (THIOPHEN 3 YL)PYRIDIN 2 YL]PHENOL; 3 [6 (FURAN 2 YL) 4 PHENYLPYRIDIN 2 YL]PHENOL; 3,3' (4 PHENYLPYRIDINE 2,6 DIYL)DIPHENOL; 4 (4 PHENYL 2,3' BIPYRIDIN 6 YL)PHENOL; 4 (4,6 DIPHENYLPYRIDIN 2 YL)PHENOL; 4 (6 PHENYL 2,4' BIPYRIDIN 4 YL)PHENOL; 4 [2 (FURAN 2 YL) 6 PHENYLPYRIDIN 4 YL]PHENOL; 4 [4 PHENYL 6 (THIOPHEN 2 YL)PYRIDIN 2 YL]PHENOL; 4 [4 PHENYL 6 (THIOPHEN 3 YL)PYRIDIN 2 YL]PHENOL; 4 [6 (FURAN 2 YL) 4 PHENYLPYRIDIN 2 YL]PHENOL; 4,4' (4 PHENYLPYRIDINE 2,6 DIYL)DIPHENOL; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOTOXINS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PYRIDINES;

EID: 77951204579     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.03.051     Document Type: Article

References (30)

1. Li T.K., and Liu L.F. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 53
2. Pommier Y. Chem. Rev. 109 (2009) 2894
3. Staker B.L., Feese M.D., Cushman M., Pommier Y., Zembower D., Stewart L., and Burgin A.B. J. Med. Chem. 48 (2005) 2336
4. Champoux J.J. Annu. Rev. Biochem. 70 (2001) 369
5. Wang J.C. Nat. Rev. Cancer 3 (2002) 430
6. Gijn R.V., Lendfers R.R.H., Schellens J.H.M., Bult A., and Beijnen J.H. J. Oncol. Pharm. Practice 3 (2000) 92
7. Schubert U.S., and Eschbaumer C. Angew. Chem., Int. Ed. 41 (2002) 2892
8. Lowe G., Droz A.S., Vilaivan T., Weaver G.W., Park J.J., Pratt J.M., Tweedale L., and Kelland L.R. J. Med. Chem. 42 (1999) 3167
9. Carter P.J., Cheng C.C., and Thorp H.H. J. Am. Chem. Soc. 120 (1998) 632
10. McCoubrey A., Latham H.C., Cook P.R., Rodger A., and Lowe G. FEBS Lett. 380 (1996) 73
11. Kim D.S.H.L., Ashendel C.L., Zhou Q., Chang C.T., Lee E.-S., and Chang C.J. Bioorg. Med. Chem. Lett. 8 (1998) 2695
12. Zhao L.X., Kim T.S., Ahn S.H., Kim T.H., Kim E.K., Cho W.J., Choi H.S., Lee C.S., Kim J.A., Jeong T.C., Chang C.J., and Lee E.-S. Bioorg. Med. Chem. Lett. 11 (2001) 2659
13. Zhao L.X., Moon Y.S., Basnet A., Kim E.K., Jahng Y., Park J.G., Jeong T.C., Cho W.J., Choi S.U., Lee C.O., Lee S.Y., Lee C.S., and Lee E.-S. Bioorg. Med. Chem. Lett. 14 (2004) 1333
14. Zhao L.X., Sherchan J., Park J.K., Jahng Y., Jeong B.S., Jeong T.C., Lee C.S., and Lee E.-S. Arch. Pharm. Res. 29 (2006) 1091
15. Basnet A., Thapa P., Karki R., Na Y., Jahng Y., Jeong B.S., Jeong T.C., Lee C.S., and Lee E.-S. Bioorg. Med. Chem. 15 (2007) 4351
16. Son J.K., Zhao L.X., Basnet A., Thapa P., Karki R., Na Y., Jahng Y., Jeong T.C., Jeong B.S., Lee C.S., and Lee E.-S. Eur. J. Med. Chem. 43 (2008) 675
17. Basnet A., Thapa P., Karki R., Choi H.Y., Choi J.H., Yun M., Jeong B.S., Jahng Y., Na Y., Cho W.J., Kwon Y., Lee C.S., and Lee E.-S. Bioorg. Med. Chem. Lett. 20 (2010) 42
18. Thapa P., Karki R., Thapa U., Jahng Y., Jung M.J., Nam J.M., Na Y., Kwon Y., and Lee E.-S. Bioorg. Med. Chem. 18 (2010) 377
19. Thapa P., Karki R., Choi H.Y., Choi J.H., Yun M., Jeong B.S., Jung M.J., Nam J.M., Na Y., Cho W.J., Kwon Y., and Lee E.-S. Bioorg. Med. Chem. 18 (2010) 2245
20. Delmas D., Lancon A., Colin D., Jannin B., and Latruffe N. Curr. Drug Targets 7 (2006) 423
21. Nonn L., Duong D., and Peehl D.M. Carcinogenesis 28 (2007) 1188
22. Thangapazham R.L., Singh A.K., Sharma A., Warren J., Gaddipati J.P., and Maheshwari R.K. Cancer Lett. 245 (2007) 232
23. Cabrera M., Simoens M., Falchi G., Lavaggi M.L., Piro O.E., Castellano E.E., Vidal A., Azqueta A., Monge A., Cerain A.L., Sagrera G., Seoane G., Cerecetto H., and Gonzalez M. Bioorg. Med. Chem. 15 (2007) 3356
24. Redinbo M.R., Stewart L., Kuhn P., Champoux J.J., and Hol W.G.J. Science 279 (1998) 1504
25. Fan Y., Weinstein J.N., Kohn K.W., Shi L.M., and Pommier Y. J. Med. Chem. 41 (1998) 2216
26. Jahng Y., Zhao L.X., Moon Y.S., Basnet A., Kim E.K., Chang H.W., Ju H.K., Jeong T.C., and Lee E.-S. Bioorg. Med. Chem. Lett. 14 (2004) 2559
27. Kröhnke F. Synthesis (1976) 1
28. Kröhnke F. Angew. Chem., Int. Ed. Engl. 2 (1963) 380
29. Fukuda M., Nishio K., Kanzawa F., Ogasawara H., Ishida T., Arioka H., Bonjanowski K., Oka M., and Saijo N. Cancer Res. 56 (1996) 789
30. Kang D.H., Kim J.S., Jung M.J., Lee E.-S., Jahng Y., Kwon Y., and Na Y. Bioorg. Med. Chem. Lett. 18 (2008) 1520